Study of Pegylated Human Recombinant Arginase for Liver Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
NeoplasmHepatocellular Carcinoma
Interventions
BIOLOGICAL

Pegylated Recombinant Human Arginase I

Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses

DRUG

Doxorubicin

Weeks 13-24 (once every 3 weeks)

Trial Locations (1)

Unknown

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

collaborator

Chinese University of Hong Kong

OTHER

lead

Bio-Cancer Treatment International Limited

INDUSTRY

NCT00988195 - Study of Pegylated Human Recombinant Arginase for Liver Cancer | Biotech Hunter | Biotech Hunter